Global Ophthalmic Drugs Market Overview:
The global ophthalmic drugs market shall gain moderate traction during the forecast period (2020-2025), registering a CAGR of 4.2%. There is an increase in incidences of eye-related diseases, particularly in developing nations, over the past several years. Visual impairment is a global health concern having a negative impact on physical and mental health. The increasing patient pool of visually impaired is anticipated to boost demand for healthcare spending on ophthalmology drugs.
Global Ophthalmic Drugs Market Trends:
The number of FDA approvals for advanced therapeutics is rising. Consequently, demand for advanced ophthalmology drugs is burgeoning. For instance, in 2016, Shire introduced Xiidra, a lymphocyte function associated antigen-1 (LFA-1) antagonist for ophthalmic drugs disorders. The foremost trend in ophthalmic drugs is the attainment of adequate drug concentrations at the targeted part of the eye with minimal side effects. This rising pool of ophthalmology patients, coupled with increasing approvals for the launch of therapeutic drugs is anticipated to leverage the global ophthalmology drugs market.
Global Ophthalmic Drugs Market: By Disease-Indication:
Retinal disorders are anticipated to find major application for ophthalmic drugs, holding more than one-third of the global ophthalmology drugs market, expanding at a CAGR of 4.7% during the forecast period. The glaucoma segment is poised to capture more than two-fifths of the overall ophthalmic drugs market, expanding stagnantly at a CAGR of 3.5%.
To get the latest COVID-19 impact insights on the ophthalmic drugs market, ask an analyst here
Increasing patient pool acquiring retinal problems is a key driver augmenting growth of the retinal disorders segment. According to sources, the number of patients with age-related macular degeneration (AMD) is anticipated to rise to 288 million by 2040. Rising pool of glaucoma patients and presence of key market players like Pfizer, Inc., Novartis AG and Valeant Pharmaceuticals International, Inc. manufacturing important drugs and formulations are anticipated to leverage market share of glaucoma drugs.
Global Ophthalmic Drugs Market: Regional Insights:
North America is poised to capture a majority of the global ophthalmic drugs market share (~2/5th) while the Asia-Pacific region is anticipated to expand at a CAGR of 4.9% during the forecast period. High cost of prescription drugs and the presence of key market players such as shall burgeon the North American ophthalmic drugs market.
To get in-depth regional insights on the ophthalmic drugs market, request for a report sample here
Increasing investments by major market players and research institutes for innovations in the ophthalmic space are key growth drivers of the Asia-Pacific. There is immense government support regarding funding of research institutions to facilitate studies in ophthalmic drugs.
Opthalmic Drug Market Manufacturers
The global ophthalmic drugs market is consolidated. The top four players constitute more than three-fifths of the market. These players are Novartis AG, Regeneron Pharmaceuticals, Inc., ALLERGAN and Santen Pharmaceutical Co., Ltd. These companies primarily concentrate on developing new drugs and innovating their development formula.
For example, Santen Pharmaceutical Co. and Singapore Eye Research Institute announced a strategic, five-year extended collaboration to develop new technologies for unmet medical needs in key ophthalmic drugs domains in 2017. The company manufactures prescription drugs for corneal, retinal and glaucoma diseases, which include Diquas, Tapros, Alesion and Eylea. Novartis AG, another player, integrates new products into its existing pipeline of drugs. It specializes in innovative medicines and includes ophthalmic drugs products like Lucentis and Travoprost.
COVID-19’s Impact on the Ophthalmic Drugs Market:
The outbreak of the coronavirus disease has presented credible opportunities for the expansion of the ophthalmic drugs market. There have been multiple reports about eye redness and irritation in COVID-19 patients, suggesting that conjunctivitis could be an ocular manifestation of COVID-19 infection. It was concluded in 2003 during the outbreak of SARS that lack of eye protection was the primary cause of transmission of the virus. A similar trend has been observed in the current wave of infections. However, most ocular manifestation of COVID-19 are self-limited and can be managed with symptomatic care.
With several countries easing social distancing measures, the supply chain of ophthalmic drugs market is anticipated to function normally. In light of the abovementioned trends, hospitals and other healthcare settings will demand increased quantities of ophthalmic drugs as a precautionary measure. With the logistical arrangements reverting to normal, availability of such drugs will become much easier. Moreover, leading manufacturers have been increasing their productive capacities and are optimistic about registering an uptick in their operations in the wake of the easing of restrictions.
Analyst’s Viewpoint:
“Rising prevalence of visual impairments has prompted healthcare providers to accelerate ophthalmic treatment across the world. This has motivated market players to develop important drugs, thereby leveraging prospects of the global ophthalmic drugs market. North America and Asia-Pacific shall generate the largest demand for ophthalmic drugs in the future.”
Global Ophthalmic Drugs Market: Report Scope:
The recent study undertaken by Fact.MR on the global ophthalmic drugs market provides a 5-year forecast period ranging from 2020 to 2025 and explicates on key dynamics impacting the market’s growth such as the drivers, opportunities and restraints. The ophthalmic drugs market has been analyzed in detail, providing information on the revenue, market share and yearly growth opportunities. Moreover, the market has been segmented based on disease indication, therapeutic class, product type and distribution channels.
The report also includes a detailed regional landscape based on the following geographies: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Each regional profile incorporates the abovementioned segments. Towards the end, a competition landscape has also been given. In this section, key companies’ revenue and market shares, product launches and important collaborations with other players have been provided. In order to provide a realistic outlook, each company is also provided with a SWOT analysis.
Global Ophthalmic Drugs Market- Scope of the Report
The recent study by Fact.MR on global ophthalmic drugs market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that are currently determining the growth of the global ophthalmic drugs market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of ophthalmic drugs. The study also provides dynamics that are responsible for influencing the future status of the global ophthalmic drugs market over the forecast period.
A detailed assessment of the global ophthalmic drugs market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global ophthalmic drugs market along with their product portfolio enhances the reliability of this comprehensive research study.
Global Ophthalmic Drugs Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global ophthalmic drugs market across the globe.
A comprehensive estimate of the global ophthalmic drugs market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global ophthalmic drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Global Ophthalmic Drugs Market Segmentation
Fact.MR has studied the global ophthalmic drugs market with detailed segmentation on the basis of disease indication, therapeutic class, product type, distribution channels and regions.
|
Disease Indication |
Therapeutic Class |
Product Type |
Distribution Channels |
Region |
|
Dry Eye |
Anti-inflammatory Drugs: NSAIDs Steroids |
Prescription Drugs |
Hospital Pharmacies |
North America |
|
Glaucoma |
Anti-infective Drugs: Anti-fungal Drugs Anti-bacterial Drugs Others |
OTC Drugs |
Online Pharmacies |
Europe |
|
Infection/Inflammation |
Anti-glaucoma Drugs: Alpha Agonist Beta Blockers Prostaglandin Analogs Combined Medication Others |
|
Independent Pharmacies & Drug Stores |
Asia Pacific |
|
Retinal Disorders: Wet AMD Dry AMD Diabetic Retinopathy Others |
Anti-allergy Drugs |
|
|
Latin America |
|
Allergy |
Anti-VEGF Drugs |
|
|
Middle East & Africa (MEA) |
|
Uveitis |
Others |
|
|
|
|
Others |
|
|
|
|
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Global Ophthalmic Drugs Market: Analysis on Market Size Evaluation
The global ophthalmic drugs market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for ophthalmic drugs is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent ophthalmic drugs market segments, along with market attractiveness evaluation has been incorporated in the report.
Global Ophthalmic Drugs Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the global ophthalmic drugs report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global ophthalmic drugs market during the forecast period.
Country-specific valuation on demand for ophthalmic drugs has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
Global Ophthalmic Drugs Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading manufacturers of global ophthalmic drugs along with their detailed profiles. Essential and up-to-date data and information related to the market performers, who are principally engaged in the production of ophthalmic drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global ophthalmic drugs market. Prominent manufacturers with established market presence in the global ophthalmic drugs market are Allergen, Bausch & Lomb Incorporated (Valeant Pharmaceuticals International, Inc.), Genentech, Inc., (F. Hoffmann- La Roche Ltd.), Novartis AG, Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, Inc., Bayer AG, Pfizer, Inc., to name a few.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.4.4. Trends
4.5. Global Ophthalmic Drugs Market Analysis and Forecasts, 2020–2025
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Market Outlook
4.8. Global Company Share Analysis: Glaucoma; 2018
4.9. Pipeline Analysis: Major Market Players
4.10. Pipeline Analysis: Emerging Market Players
4.11. Comparison matrix for product offerings: Major Market Players
4.12. Snapshot: Causes of blindness - Global
4.13. Snapshot: Causes of blindness - Regional
5. Global Ophthalmic Drugs Market Analysis and Forecasts, By Disease Indication
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast by Disease Indication, 2020–2025
5.4.1. Dry Eye
5.4.2. Glaucoma
5.4.3. Infection/Inflammation
5.4.4. Retinal Disorders
5.4.4.1. Wet AMD
5.4.4.2. Dry AMD
5.4.4.3. Diabetic Retinopathy
5.4.4.4. Others
5.4.5. Allergy
5.4.6. Uveitis
5.4.7. Others
5.5. Market Attractiveness by Disease Indication
6. Global Ophthalmic Drugs Market Analysis and Forecasts, By Therapeutic Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast By Therapeutic Class, 2020–2025
6.4.1. Anti-inflammatory Drugs
6.4.1.1. NSAID
6.4.1.2. Steroids
6.4.2. Anti-infective Drugs
6.4.2.1. Anti-fungal Drugs
6.4.2.2. Anti-bacterial Drugs
6.4.2.3. Others
6.4.3. Anti-glaucoma Drugs
6.4.3.1. Alpha Agonist
6.4.3.2. Beta Blockers
6.4.3.3. Prostaglandin Analogs
6.4.3.4. Combined Medication
6.4.3.5. Others
6.4.4. Anti-allergy Drugs
6.4.5. Anti-VEGF Agents
6.4.6. Others
6.5. Market Attractiveness by Therapeutic Class
7. Global Ophthalmic Drugs Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast by Product Type, 2020–2025
7.4.1. Prescription Drugs
7.4.2. OTC Drugs
7.5. Market Attractiveness by Product Type
8. Global Ophthalmic Drugs Market Analysis and Forecasts, By Distribution Channels
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Value Forecast by Distribution Channels, 2020–2025
8.4.1. Hospital Pharmacies
8.4.2. Online Pharmacies
8.4.3. Independent Pharmacies & Drug Stores
8.5. Market Attractiveness by Distribution Channels
9. Global Ophthalmic Drugs Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Policies and Regulations
9.3. Market Value Forecast by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East and Africa
9.4. Market Attractiveness by Country/Region
10. North America Ophthalmic Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast by Disease Indication, 2020–2025
10.2.1. Dry Eye
10.2.2. Glaucoma
10.2.3. Infection/Inflammation
10.2.4. Retinal Disorders
10.2.4.1. Wet AMD
10.2.4.2. Dry AMD
10.2.4.3. Diabetic Retinopathy
10.2.4.4. Others
10.2.5. Allergy
10.2.6. Uveitis
10.2.7. Others
10.3. Market Value Forecast by Therapeutic Class, 2020–2025
10.3.1. Anti-inflammatory Drugs
10.3.1.1. NSAID
10.3.1.2. Steroids
10.3.2. Anti-infective Drugs
10.3.2.1. Anti-fungal Drugs
10.3.2.2. Anti-bacterial Drugs
10.3.2.3. Others
10.3.3. Anti-glaucoma Drugs
10.3.3.1. Alpha Agonist
10.3.3.2. Beta Blockers
10.3.3.3. Prostaglandin Analogs
10.3.3.4. Combined Medication
10.3.3.5. Others
10.3.4. Anti-allergy Drugs
10.3.5. Anti-VEGF Agents
10.3.6. Others
10.4. Market Value Forecast by Product Type, 2020–2025
10.4.1. Prescription Drugs
10.4.2. OTC Drugs
10.5. Market Value Forecast by Distribution Channels, 2020–2025
10.5.1. Hospital Pharmacies
10.5.2. Online Pharmacies
10.5.3. Independent Pharmacies & Drug Stores
10.6. Market Value Forecast by Country, 2020–2025
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease Indication
10.7.2. By Therapeutic Class
10.7.3. By Product Type
10.7.4. By Distribution Channels
10.7.5. By Country
11. Europe Ophthalmic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Key Trends
11.2. Market Value Forecast by Disease Indication, 2020–2025
11.2.1. Dry Eye
11.2.2. Glaucoma
11.2.3. Infection/Inflammation
11.2.4. Retinal Disorders
11.2.4.1. Wet AMD
11.2.4.2. Dry AMD
11.2.4.3. Diabetic Retinopathy
11.2.4.4. Others
11.2.5. Allergy
11.2.6. Uveitis
11.2.7. Others
11.3. Market Value Forecast by Therapeutic Class, 2020–2025
11.3.1. Anti-inflammatory Drugs
11.3.1.1. NSAID
11.3.1.2. Steroids
11.3.2. Anti-infective Drugs
11.3.2.1. Anti-fungal Drugs
11.3.2.2. Anti-bacterial Drugs
11.3.2.3. Others
11.3.3. Anti-glaucoma Drugs
11.3.3.1. Alpha Agonist
11.3.3.2. Beta Blockers
11.3.3.3. Prostaglandin Analogs
11.3.3.4. Combined Medication
11.3.3.5. Others
11.3.4. Anti-allergy Drugs
11.3.5. Anti-VEGF Agents
11.3.6. Others
11.4. Market Value Forecast by Product Type, 2020–2025
11.4.1. Prescription Drugs
11.4.2. OTC Drugs
11.5. Market Value Forecast by Distribution Channels, 2020–2025
11.5.1. Hospital Pharmacies
11.5.2. Online Pharmacies
11.5.3. Independent Pharmacies & Drug Stores
11.6. Market Value Forecast by Country, 2020–2025
11.6.1. U.K.
11.6.2. Germany
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Russia
11.6.7. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Therapeutic Class
11.7.3. By Product Type
11.7.4. By Distribution Channels
11.7.5. By Country
12. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Key Trends
12.2. Market Value Forecast by Disease Indication, 2020–2025
12.2.1. Dry Eye
12.2.2. Glaucoma
12.2.3. Infection/Inflammation
12.2.4. Retinal Disorders
12.2.4.1. Wet AMD
12.2.4.2. Dry AMD
12.2.4.3. Diabetic Retinopathy
12.2.4.4. Others
12.2.5. Allergy
12.2.6. Uveitis
12.2.7. Others
12.3. Market Value Forecast by Therapeutic Class, 2020–2025
12.3.1. Anti-inflammatory Drugs
12.3.1.1. NSAID
12.3.1.2. Steroids
12.3.2. Anti-infective Drugs
12.3.2.1. Anti-fungal Drugs
12.3.2.2. Anti-bacterial Drugs
12.3.2.3. Others
12.3.3. Anti-glaucoma Drugs
12.3.3.1. Alpha Agonist
12.3.3.2. Beta Blockers
12.3.3.3. Prostaglandin Analogs
12.3.3.4. Combined Medication
12.3.3.5. Others
12.3.4. Anti-allergy Drugs
12.3.5. Anti-VEGF Agents
12.3.6. Others
12.4. Market Value Forecast by Product Type, 2020–2025
12.4.1. Prescription Drugs
12.4.2. OTC Drugs
12.5. Market Value Forecast by Distribution Channels, 2020–2025
12.5.1. Hospital Pharmacies
12.5.2. Online Pharmacies
12.5.3. Independent Pharmacies & Drug Stores
12.6. Market Value Forecast by Country, 2020–2025
12.6.1. India
12.6.2. China
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Therapeutic Class
12.7.3. By Product Type
12.7.4. By Distribution Channels
12.7.5. By Country
13. Latin America Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Key Trends
13.2. Market Value Forecast by Disease Indication, 2020–2025
13.2.1. Dry Eye
13.2.2. Glaucoma
13.2.3. Infection/Inflammation
13.2.4. Retinal Disorders
13.2.4.1. Wet AMD
13.2.4.2. Dry AMD
13.2.4.3. Diabetic Retinopathy
13.2.4.4. Others
13.2.5. Allergy
13.2.6. Uveitis
13.2.7. Others
13.3. Market Value Forecast by Therapeutic Class, 2020–2025
13.3.1. Anti-inflammatory Drugs
13.3.1.1. NSAID
13.3.1.2. Steroids
13.3.2. Anti-infective Drugs
13.3.2.1. Anti-fungal Drugs
13.3.2.2. Anti-bacterial Drugs
13.3.2.3. Others
13.3.3. Anti-glaucoma Drugs
13.3.3.1. Alpha Agonist
13.3.3.2. Beta Blockers
13.3.3.3. Prostaglandin Analogs
13.3.3.4. Combined Medication
13.3.3.5. Others
13.3.4. Anti-allergy Drugs
13.3.5. Anti-VEGF Agents
13.3.6. Others
13.4. Market Value Forecast by Product Type, 2020–2025
13.4.1. Prescription Drugs
13.4.2. OTC Drugs
13.5. Market Value Forecast by Distribution Channels, 2020–2025
13.5.1. Hospital Pharmacies
13.5.2. Online Pharmacies
13.5.3. Independent Pharmacies & Drug Stores
13.6. Market Value Forecast by Country, 2020–2025
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Therapeutic Class
13.7.3. By Product Type
13.7.4. By Distribution Channels
13.7.5. By Country
14. Middle East and Africa Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.1.2. Policies and Regulations
14.1.3. Key Trends
14.2. Market Value Forecast by Disease Indication, 2020–2025
14.2.1. Dry Eye
14.2.2. Glaucoma
14.2.3. Infection/Inflammation
14.2.4. Retinal Disorders
14.2.4.1. Wet AMD
14.2.4.2. Dry AMD
14.2.4.3. Diabetic Retinopathy
14.2.4.4. Others
14.2.5. Allergy
14.2.6. Uveitis
14.2.7. Others
14.3. Market Value Forecast by Therapeutic Class, 2020–2025
14.3.1. Anti-inflammatory Drugs
14.3.1.1. NSAID
14.3.1.2. Steroids
14.3.2. Anti-infective Drugs
14.3.2.1. Anti-fungal Drugs
14.3.2.2. Anti-bacterial Drugs
14.3.2.3. Others
14.3.3. Anti-glaucoma Drugs
14.3.3.1. Alpha Agonist
14.3.3.2. Beta Blockers
14.3.3.3. Prostaglandin Analogs
14.3.3.4. Combined Medication
14.3.3.5. Others
14.3.4. Anti-allergy Drugs
14.3.5. Anti-VEGF Agents
14.3.6. 14.3.6. Others
14.4. Market Value Forecast by Product Type, 2020–2025
14.4.1. Prescription Drugs
14.4.2. OTC Drugs
14.5. Market Value Forecast by Distribution Channels, 2020–2025
14.5.1. Hospital Pharmacies
14.5.2. Online Pharmacies
14.5.3. Independent Pharmacies & Drug Stores
14.6. Market Value Forecast by Country, 2020–2025
14.6.1. South Africa
14.6.2. GCC Countries
14.6.3. Rest of Middle East and Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Therapeutic Class
14.7.3. By Product Type
14.7.4. 14.7.4. By Distribution Channels
14.7.5. 14.7.5. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis by Company (2018)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Aerie Pharmaceuticals, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. ALLERGAN
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Valeant Pharmaceuticals International, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Bayer AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Novartis AG
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Pfizer Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Regeneron Pharmaceuticals, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Santen Pharmaceutical Co., Ltd.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Shire
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.10.6. Others
Fact.MR offers custom research services that help clients to get specific research solutions
Related reports
We are committed towards customer satisfaction and quality service.
Opthalmic Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025